| Hans-Günter Meyer-Thompson | HIV
FDA approval of injectable lenacapavir marks progress for HIV prevention
FDA approval of injectable lenacapavir marks progress for HIV prevention
The World Health Organization (WHO) welcomes the approval by the United States Food and Drug Administration (FDA) of injectable lenacapavir for HIV prevention.
This milestone follows promising 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated the safety and efficacy of lenacapavir across diverse populations and settings. Administered just twice a year, lenacapavir offers sustained protection and adds to the growing range of HIV prevention options. (WHO, Genf, 19.06.2025)
https://www.who.int/news/item/19-06-2025-fda-approval-of-injectable-lenacapavir-marks-progress-for-hiv-prevention